BE2022C501I2 - - Google Patents

Download PDF

Info

Publication number
BE2022C501I2
BE2022C501I2 BE2022C501C BE2022C501C BE2022C501I2 BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2 BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2
Authority
BE
Belgium
Application number
BE2022C501C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2022C501I2 publication Critical patent/BE2022C501I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE2022C501C 2003-01-29 2022-01-03 BE2022C501I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003020854 2003-01-29

Publications (1)

Publication Number Publication Date
BE2022C501I2 true BE2022C501I2 (en) 2023-03-07

Family

ID=32820637

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2022C501C BE2022C501I2 (en) 2003-01-29 2022-01-03

Country Status (26)

Country Link
US (4) US7300935B2 (en)
EP (1) EP1591446B1 (en)
KR (1) KR101074462B1 (en)
CN (2) CN100360538C (en)
AU (1) AU2004207706B2 (en)
BE (1) BE2022C501I2 (en)
BR (1) BRPI0407082C1 (en)
CA (1) CA2514407C (en)
CO (1) CO5590921A2 (en)
CY (2) CY1114008T1 (en)
DK (1) DK1591446T3 (en)
ES (1) ES2410814T3 (en)
FR (1) FR21C1056I2 (en)
HU (1) HUS2100052I1 (en)
IL (1) IL169869A (en)
LT (1) LTC1591446I2 (en)
MX (1) MXPA05007990A (en)
NL (1) NL301158I2 (en)
NO (2) NO331981B1 (en)
NZ (1) NZ541772A (en)
PL (1) PL214756B1 (en)
PT (1) PT1591446E (en)
RU (1) RU2331648C2 (en)
SI (1) SI1591446T1 (en)
WO (1) WO2004067535A1 (en)
ZA (1) ZA200506611B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
NZ566038A (en) * 2005-07-22 2011-06-30 Takeda Pharmaceutical The use of thieno(2,3-d)pyrimidine-2,4-dione derivatives which are gonadotropin releasing hormone (GnRH) antagonists as premature ovulation preventive agent
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
KR20140094590A (en) 2009-01-08 2014-07-30 쿠리스 인코퍼레이션 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
HRP20160545T1 (en) 2011-04-01 2016-06-17 Curis, Inc. 3-KINASE PHOSPHOINOSITIDE INHIBITOR WITH ZINC BINDING PART
UA123760C2 (en) * 2011-11-11 2021-06-02 Гіліад Аполло, Ллс COMPOUND (OPTIONS) AND COMPOSITION CONTAINING COMPOUND
HUE059077T2 (en) * 2012-09-28 2022-11-28 Takeda Pharmaceuticals Co 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3 Crystalline form of -D)-pyrimidin-6-yl)phenyl)-3-methoxyurea
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
US10350170B2 (en) 2015-02-26 2019-07-16 Takeda Pharmaceutical Company Limited Solid preparation
CN107922609B (en) 2015-07-01 2020-04-24 加州理工学院 Delivery system based on cationic mucic acid polymers
AR106472A1 (en) 2015-10-26 2018-01-17 Gilead Apollo Llc ACC INHIBITORS AND USES OF THE SAME
JP2019503338A (en) 2015-11-25 2019-02-07 ギリアド アポロ, エルエルシー Fungicidal composition comprising a derivative of 2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidine
PL3380480T3 (en) 2015-11-25 2023-05-08 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
CA3005900C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Triazole acc inhibitors and uses thereof
RU2610281C1 (en) * 2016-02-26 2017-02-08 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Method for production of 2-fluorine-3-methylbut-2-enyl amine or its hydrochloride (versions)
CN108699078A (en) 2016-03-02 2018-10-23 吉利德阿波罗公司 Solid forms of thienopyrimidinedione ACC inhibitors and methods of making the same
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
CA3038879A1 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
KR20220119520A (en) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 Therapeutic combinations for treating liver diseases
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11306104B2 (en) 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
MA53619A (en) 2018-09-11 2021-12-15 Curis Inc POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL
WO2020089190A2 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
WO2020230094A1 (en) * 2019-05-15 2020-11-19 Dr. Reddy’S Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (en) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 Synthetic method of Ruogeli
CN111943960B (en) * 2019-07-29 2022-02-15 广东东阳光药业有限公司 Substituted pyrimidinediones and uses thereof
WO2021026011A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112321602A (en) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 Preparation method of Ruogeli drug intermediate
AU2020325721A1 (en) 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
CN114466665A (en) 2019-08-08 2022-05-10 奥布赛瓦股份公司 Compositions and methods for treating estrogen-dependent conditions
CN112390812A (en) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 Crystalline and amorphous solids of Ruogeli compounds and methods of making the same
WO2021031148A1 (en) * 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 Crystal form of gonadotropin releasing hormone antagonist, preparation method therefor, and use thereof
CN115175912B (en) * 2019-10-10 2025-04-11 住友制药瑞士有限公司 Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-D]pyrimidin-6-yl)phenyl)-N′-methoxyurea
EP4041739A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
CN112745304A (en) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 Preparation method of Relugolix and intermediate compound
CN113444105A (en) * 2020-03-27 2021-09-28 南京海润医药有限公司 Preparation method of Relugolix
CN111333633B (en) * 2020-04-01 2023-10-20 江西科睿药业有限公司 Intermediate compound of Rayleigh Lu Geli and preparation method and application thereof
CN111574534B (en) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
WO2021239917A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
CN111875614B (en) * 2020-07-03 2022-04-29 东莞市东阳光新药研发有限公司 Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
CN111793078B (en) * 2020-07-03 2022-02-01 东莞市东阳光新药研发有限公司 Bicyclic nitrogen-containing heteroaryl substituted pyrimidinediones and application thereof
CN111925379B (en) * 2020-07-31 2022-02-15 广东东阳光药业有限公司 Nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof
CN111909168B (en) * 2020-07-31 2022-02-01 广东东阳光药业有限公司 Nitrogenous heterocyclic group substituted pyrimidinediones and uses thereof
CN113754679B (en) * 2020-09-09 2023-04-07 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN112047957B (en) * 2020-09-09 2022-02-01 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN112142757B (en) * 2020-09-29 2022-02-15 广东东阳光药业有限公司 Five-membered nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (en) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 Synthetic method of Ruogeli or salt thereof
CN113620972A (en) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 Rugosril new crystal form and preparation method thereof
CN114907370B (en) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 High purity thienopyrimidine compounds and process for their preparation
CN115073491A (en) * 2021-03-12 2022-09-20 上海医药工业研究院 Rugosril intermediate, preparation method and application thereof
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CN113135934A (en) * 2021-04-28 2021-07-20 北京海美源医药科技有限公司 Intermediate compound for preparing Ruugeli, preparation method of intermediate compound and preparation method of Ruugeli
CN115260211B (en) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 Thiophene condensed ring derivative, pharmaceutical composition, preparation method and application thereof
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023072284A1 (en) * 2021-11-01 2023-05-04 山东绿叶制药有限公司 Gonadotropin-releasing hormone antagonist, and preparation method therefor and use thereof
CN114230576A (en) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 A kind of preparation method of Relugoli
CN114989134B (en) * 2022-07-14 2023-11-14 江西同和药业股份有限公司 Thiophene compound and preparation method and application thereof
CN115417883B (en) * 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 Crystal form of rui Lu Geli and preparation method thereof
WO2024126674A1 (en) 2022-12-15 2024-06-20 Medichem, S.A. Process for the preparation of relugolix
WO2024222827A1 (en) * 2023-04-27 2024-10-31 山东绿叶制药有限公司 Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
UY23948A1 (en) 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd DERIVATIVES FROM THYPHENE CONDENSED RINGS, THEIR PRODUCTION AND USE.
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US6297379B1 (en) * 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
CN1173977C (en) * 2000-02-29 2004-11-03 武田药品工业株式会社 Process for preparing thienopyrimidine derivatives
JP2001316391A (en) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd Method for producing thienopyridine derivative
JP2001354588A (en) * 2000-04-13 2001-12-25 Takeda Chem Ind Ltd Prophylactic and therapeutic agent for alzheimer disease
EP1393747A1 (en) * 2000-04-13 2004-03-03 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
JP2002068982A (en) * 2000-06-14 2002-03-08 Takeda Chem Ind Ltd Sustained release composition
US20040023987A1 (en) * 2000-06-14 2004-02-05 Yoshio Hata Sustained release compositions
JP2002080397A (en) * 2000-07-05 2002-03-19 Takeda Chem Ind Ltd Therapeutic pharmaceutical formulation for sex hormone-dependent disease
AU2001269439A1 (en) 2000-07-05 2002-01-14 Takeda Chemical Industries Ltd. Medicinal preparations for treating sex hormone-dependent diseases
JP2002167327A (en) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd Solid formulation
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
WO2002047722A1 (en) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
MXPA03004926A (en) * 2001-02-14 2005-02-14 Warner Lambert Co Thieno 2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors.
JP5072166B2 (en) * 2002-01-30 2012-11-14 武田薬品工業株式会社 Thienopyrimidine compound, production method and use thereof
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
EP1488807A4 (en) 2002-03-11 2009-07-08 Takeda Pharmaceutical MEDICAMENTS FOR TREATING SEXUAL HORMONE DEPENDENT DISEASE
JP2004002321A (en) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd Therapeutic agent for sex hormone dependent disease
JP2004002377A (en) * 2002-04-12 2004-01-08 Takeda Chem Ind Ltd Hot flash preventing and treating agent
US20050250793A1 (en) 2002-04-12 2005-11-10 Masami Kusaka Preventives/remedies for hot flash

Also Published As

Publication number Publication date
NL301158I2 (en) 2022-05-25
PL378002A1 (en) 2006-02-20
US20080108623A1 (en) 2008-05-08
RU2005127052A (en) 2006-02-10
US20060160829A1 (en) 2006-07-20
CY2021039I1 (en) 2022-03-24
DK1591446T3 (en) 2013-06-10
KR101074462B1 (en) 2011-10-18
HUS2100052I1 (en) 2021-12-28
CN101153042A (en) 2008-04-02
BRPI0407082B8 (en) 2019-06-25
US9346822B2 (en) 2016-05-24
CY2021039I2 (en) 2022-03-24
RU2331648C2 (en) 2008-08-20
AU2004207706B2 (en) 2010-03-04
BRPI0407082C1 (en) 2021-05-25
NZ541772A (en) 2009-10-30
WO2004067535A1 (en) 2004-08-12
NO331981B1 (en) 2012-05-21
AU2004207706A1 (en) 2004-08-12
US7300935B2 (en) 2007-11-27
PT1591446E (en) 2013-06-12
EP1591446A1 (en) 2005-11-02
ZA200506611B (en) 2006-12-27
BRPI0407082B1 (en) 2019-06-04
CA2514407A1 (en) 2004-08-12
CY1114008T1 (en) 2016-07-27
EP1591446B1 (en) 2013-03-06
LTC1591446I2 (en) 2023-04-25
CA2514407C (en) 2012-01-03
PL214756B1 (en) 2013-09-30
SI1591446T1 (en) 2013-07-31
US20140221381A1 (en) 2014-08-07
ES2410814T3 (en) 2013-07-03
US8735401B2 (en) 2014-05-27
CN100360538C (en) 2008-01-09
US8058280B2 (en) 2011-11-15
NO20053974D0 (en) 2005-08-25
NO2021052I1 (en) 2021-12-16
FR21C1056I2 (en) 2022-11-18
KR20050096171A (en) 2005-10-05
HK1084665A1 (en) 2006-08-04
US20120071486A1 (en) 2012-03-22
LTPA2021529I1 (en) 2021-12-10
CN1768065A (en) 2006-05-03
MXPA05007990A (en) 2005-09-20
EP1591446A4 (en) 2008-04-30
NO20053974L (en) 2005-10-27
CO5590921A2 (en) 2005-12-30
FR21C1056I1 (en) 2022-01-21
IL169869A (en) 2011-10-31
BRPI0407082A (en) 2006-01-24

Similar Documents

Publication Publication Date Title
BE2022C501I2 (en)
BE2013C075I2 (en)
BE2013C069I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
BE2013C034I2 (en)
JP2003271400A5 (en)
JP2004005419A5 (en)
BE2012C053I2 (en)
JP2004182218A5 (en)
JP2004000632A5 (en)
JP2003288198A5 (en)
JP2004034026A5 (en)
DK200200343U3 (en)
JP2004215922A5 (en)
AU2002311957A1 (en)
AU2002255066A1 (en)
AU2002345911A1 (en)
AU2002310561A1 (en)
AU2002324323A1 (en)
AU2002316511A1 (en)
AU2002256398A1 (en)
AU2002348177A1 (en)